Home>Topics>Finance>Technology>Biotechnology

Biotechnology

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Morningstar's Most Popular

    Headlines

    Fri, 27 Mar 2015

    Requested Fund Quotes Fidelity Select Biotechnology Portfolio Vanguard 500 Index Vanguard ..... Market SPDR S&P 500 iShares Nasdaq Biotechnology PowerShares QQQ Vanguard Dividend Appreciation ..... Vanguard Health Care iShares Nasdaq Biotechnology Vanguard Total Stock Market

  2. New Cancer Drugs: First Movers Will Win

    Video Reports

    Fri, 27 Mar 2015

    implications for the moats of companies in the pharmaceutical and biotech sector. Immuno-oncology drugs work by basically harnessing ..... AZN] AstraZeneca (AZN) are also well positioned. On the biotech side, we thing Insight has some attractive early-stage assets

    biotech found at 0:19, 1:39

    course, have implications for the moats of companies in the pharmaceutical and biotech sector. Immuno-oncology drugs work by basically harnessing the patient's own immune system to target their tumors. The results from these drugs have
    both Roche (ROG) and [TICKER:AZN] AstraZeneca (AZN) are also well positioned. On the biotech side, we thing Insight has some attractive early-stage assets. Of the companies I just mentioned, Merck is currently the most undervalued. It
  3. U.S. biotech stocks may fall further as short interest rises

    Headlines

    Fri, 27 Mar 2015

    NEW YORK (Reuters) - A 4 percent decline in biotechnology stocks on Wednesday sent the Nasdaq Composite Index to its largest one-day loss in nearly a year, and some investors are betting that the once-hot sector has further to fall.

  4. ANALYSIS-U.S. biotech stocks may fall further as short interest rises

    Headlines

    Fri, 27 Mar 2015

    NEW YORK, March 27 (Reuters) - A 4 percent decline in biotechnology stocks on Wednesday sent the Nasdaq Composite Index to its largest one-day loss in nearly a year, and some investors are betting...

  5. UPDATE 1-Two experimental Ebola vaccines pass safety test in African trial

    Headlines

    Thu, 26 Mar 2015

    NEW YORK, March 26 (Reuters) - Two experimental Ebola vaccines, one from GlaxoSmithKline PLC and the other from biotech start-up NewLink Genetics Corp, "appear to be safe" part way through a clinical trial being conducted in Liberia, the

  6. Two experimental Ebola vaccines pass safety test in African trial

    Headlines

    Thu, 26 Mar 2015

    NEW YORK, March 26 (Reuters) - Two experimental Ebola vaccines, one from GlaxoSmithKline PLC and the other from biotech start-up NewLink Genetics Corp, "appear to be safe" part way through a clinical trial being conducted in Liberia, the

  7. First-Quarter Leaders and Laggards: Equity Funds

    Video Reports

    Thu, 26 Mar 2015

    growth was the best-performing category, but also funds that had healthy allocations to health care and, particularly, biotech stocks did very well. A case in point is [TICKER:CSMVX] Century Small Cap Select (CSMVX), which not only is a small

    biotech found at 0:53

    but also funds that had healthy allocations to health care and, particularly, biotech stocks did very well. A case in point is [TICKER:CSMVX] Century Small Cap Select (CSMVX), which not only is a small-cap growth fund
  8. Signs of a Normalizing Market

    Headlines

    Wed, 25 Mar 2015

    and MLPs while also buying heavily into industries such as biotech and social media. In addition, non-earning companies were also ..... making companies and its large weightings in areas such as biotech , REITs, MLPs, and social media that sport indefensible valuations

  9. CLS: British Politics – Monetary Policy – Tactical Strategies

    Headlines

    Wed, 25 Mar 2015

    performance wherever it goes with minimal emphasis on diversification. In this case, the five ETFs used inside FV invest in biotech , healthcare, the Internet, consumer staples, and consumer discretionary. At CLS, our view is that investors benefit from

  10. BRIEF-Cytos Biotechnology : Novartis buys out CAD 106 license agreement for CHF 4 mln

    Headlines

    Wed, 25 Mar 2015

    * Novartis buys out CAD 106 license agreement for 4 million Swiss francs ($4 million)

« Prev12345Next »
Content Partners